Trial Outcomes & Findings for Study EvAluating Genotypes While Using Lucentis 2 (NCT NCT01464723)

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

66 participants

Primary outcome timeframe

5 years

Results posted on

2019-08-14

Participant Flow

The Principal Investigator has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful due to all study team members having left the University. No study data are available, attempts were made to find the data but were unsuccessful.

Participant milestones

Participant milestones
Measure	Lucentis Consented, enrolled subjects will receive multiple open-label intravitreally administered 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months. Ranibizumab : Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
Overall Study STARTED	0
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Study EvAluating Genotypes While Using Lucentis 2

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 5 years

Population: The Principal Investigator has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful due to all study team members having left the University. No study data are available, attempts were made to find the data but were unsuccessful.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years

Population: The Principal Investigator has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful due to all study team members having left the University. No study data are available, attempts were made to find the data but were unsuccessful.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years

Population: The Principal Investigator has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful due to all study team members having left the University. No study data are available, attempts were made to find the data but were unsuccessful.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years

Population: The Principal Investigator has left the institution. Efforts were made to contact the PI/study team members, but were unsuccessful due to all study team members having left the University. No study data are available, attempts were made to find the data but were unsuccessful.

Outcome measures

Outcome data not reported

Adverse Events

Lucentis

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Stuart Brown

University of California San Diego Shiley Eye Center

Phone: (858) 822-2585858-246-0814

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place